Drug Discoveries and Therapeutics最新文献_第9页

Inhaled ciclesonide does not affect production of antibodies or elimination of virus in patients with COVID-19: Subanalysis of a multicenter, open-label randomized trial. 吸入ciclesonide不会影响新冠肺炎患者抗体的产生或病毒的消除：一项多中心、开放标签随机试验的亚分析。

IF 3.1

Drug Discoveries and Therapeutics Pub Date : 2023-11-18 Epub Date: 2023-10-30 DOI: 10.5582/ddt.2023.01078

Manabu Suzuki, Akihiro Matsunaga, Tohru Miyoshi-Akiyama, Junko Terada-Hirashima, Kenji Sadamasu, Mami Nagashima, Jin Takasaki, Shinyu Izumi, Masayuki Hojo, Yukihito Ishizaka, Haruhito Sugiyama

{"title":"Inhaled ciclesonide does not affect production of antibodies or elimination of virus in patients with COVID-19: Subanalysis of a multicenter, open-label randomized trial.","authors":"Manabu Suzuki, Akihiro Matsunaga, Tohru Miyoshi-Akiyama, Junko Terada-Hirashima, Kenji Sadamasu, Mami Nagashima, Jin Takasaki, Shinyu Izumi, Masayuki Hojo, Yukihito Ishizaka, Haruhito Sugiyama","doi":"10.5582/ddt.2023.01078","DOIUrl":"10.5582/ddt.2023.01078","url":null,"abstract":"During an earlier multicenter, open-label, randomized controlled trial designed to evaluate the effectiveness of high-dose inhaled ciclesonide in patients with asymptomatic or mild coronavirus disease 2019 (COVID-19), we observed that worsening of shadows on CT without worsening of clinical symptoms was more common with ciclesonide. The present study sought to determine if an association exists between worsening CT shadows and impaired antibody production in patients treated with inhaled ciclesonide. Eighty-nine of the 90 patients in the original study were prospectively enrolled. After exclusions, there were 36 patients each in the ciclesonide and control groups. We analyzed antibody titers against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid protein at various time points. Changes in viral load during treatment were compared. There was no significant difference in age, sex, body mass index, background clinical characteristics, or symptoms between the two groups. Although evaluation on day 8 suggested a greater tendency for worsening shadows on CT in the ciclesonide group (p = 0.072), there was no significant difference between them in the ability to produce antibodies (p = 0.379) or the maximum antibody titer during the clinical course. In both groups, worsening CT shadows and higher viral loads were observed on days 1-8, suggesting ciclesonide does not affect clearance of the virus (p = 0.134). High-dose inhaled ciclesonide did not impair production of antibodies against SARS-CoV-2 or affect elimination of the virus, suggesting that this treatment can be used safely in patients with COVID-19 patients who use inhaled steroids for asthma and other diseases.","PeriodicalId":47494,"journal":{"name":"Drug Discoveries and Therapeutics","volume":" ","pages":"304-311"},"PeriodicalIF":3.1,"publicationDate":"2023-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71414711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

EQUIBIND: A geometric deep learning-based protein-ligand binding prediction method. EQUIBIND：一种基于几何深度学习的蛋白质配体结合预测方法。

IF 3.1

Drug Discoveries and Therapeutics Pub Date : 2023-11-18 Epub Date: 2023-09-26 DOI: 10.5582/ddt.2023.01063

Yuze Li, Li Li, Shuang Wang, Xiaowen Tang

引用次数: 0

Efficacy of Andrographis paniculata spray in acute pharyngitis: A randomized controlled trial. 穿心莲喷雾剂治疗急性咽炎的疗效：一项随机对照试验。

IF 3.1

Drug Discoveries and Therapeutics Pub Date : 2023-11-18 Epub Date: 2023-10-11 DOI: 10.5582/ddt.2023.01053

Risa Okonogi, Vich Thampanya, Siriporn Okonogi

{"title":"Efficacy of Andrographis paniculata spray in acute pharyngitis: A randomized controlled trial.","authors":"Risa Okonogi, Vich Thampanya, Siriporn Okonogi","doi":"10.5582/ddt.2023.01053","DOIUrl":"10.5582/ddt.2023.01053","url":null,"abstract":"Acute viral pharyngitis is a self-limited disease but the symptoms, a sore throat in particular, can affect one's quality of life. Medicine for symptom relief is the main treatment. Recently, many studies have shown that Andrographis paniculata was efficacious in treating many diseases, including upper respiratory infections. However, adverse reactions to systemic intake are a concern. Therefore, A. paniculata spray is intended to reduce systemic adverse reactions and provide patients with more comfort as its local use. This randomized, double-blind study enrolled 60 adult patients with acute viral pharyngitis. All patients were asked to score the severity of symptoms including a sore throat, difficulty swallowing, and coughing using an 11-point numeric rating scale from 0 to 10. A physical examination was performed to score the severity of erythematous and swollen mucosa using a 0-3 score (0 = no, 1 = mild, 2 = moderate, and 3 = severe). The patients were randomized to receive treatment with either an A. paniculata spray or a positive control chamomile spray. Results revealed a significant reduction in the severity of all signs and symptoms in both groups (p < 0.05). The duration of treatment response in the A. paniculata spray group was 1.9 ± 0.7 days compared to 2.5 ± 1.2 days in the chamomile spray group (p = 0.049). No adverse events were noted in either group. A. paniculata spray is safe and highly efficacious in treating acute viral pharyngitis and can reduce symptoms more rapidly than a positive control spray.","PeriodicalId":47494,"journal":{"name":"Drug Discoveries and Therapeutics","volume":" ","pages":"340-345"},"PeriodicalIF":3.1,"publicationDate":"2023-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41216059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effects of plant-based copper nanoparticles on the elimination of ciprofloxacin. 植物基纳米铜对环丙沙星的清除作用。

IF 3.1

Drug Discoveries and Therapeutics Pub Date : 2023-11-18 Epub Date: 2023-10-16 DOI: 10.5582/ddt.2023.01057

Tanongsak Sassa-Deepaeng, Wachira Yodthong, Nattakanwadee Khumpirapang, Songyot Anuchapreeda, Siriporn Okonogi

{"title":"Effects of plant-based copper nanoparticles on the elimination of ciprofloxacin.","authors":"Tanongsak Sassa-Deepaeng, Wachira Yodthong, Nattakanwadee Khumpirapang, Songyot Anuchapreeda, Siriporn Okonogi","doi":"10.5582/ddt.2023.01057","DOIUrl":"10.5582/ddt.2023.01057","url":null,"abstract":"Ciprofloxacin (CIP) is frequently detected in the environment and causes the emergence of drug-resistant bacteria. High levels of CIP in the environment are also harmful to humans and animals. Therefore, effective elimination of CIP is required. In this study, plant-based copper nanoparticles (CuNPs) have been fabricated for the purpose of eliminating CIP. Aqueous extracts of 6 plants were compared for their phytochemicals and reducing activity. Among all the extracts, Garcinia mangostana extract (GM) was the most potent with the highest total phenolic compounds, flavonoids, tannins, terpenoids, and reducing activity. CuNPs synthesized using GM (GM-CuNPs) were characterized using UV-VIS spectroscopy and dynamic light scattering. The results showed that the maximum absorption of GM-CuNPs was at 340 nm. The average size of GM-CuNPs is in the nanoscale range of 159.2 ± 61 nm, with a narrow size distribution and a negative zeta potential of - 4.13 ± 6.97 mV. The stability of GM-CuNPs is not solely due to their zeta potential but also phytochemicals in the extract. GM-CuNPs at 25 mM showed the highest efficiency of 95% in removing CIP from aqueous medium pH 6-7 at 25-35°C within 20 min. The results indicated that the electrostatic attraction between the negative charge of GM-CuNPs and the positive charge of CIP controlled the drug adsorption on the nanoparticles. In conclusion, the developed GM-CuNPs have excellent CIP removal efficiency. These synthesized GM-CuNPs are expected to be environmentally friendly for the removal of antibiotics and other drugs.","PeriodicalId":47494,"journal":{"name":"Drug Discoveries and Therapeutics","volume":" ","pages":"320-327"},"PeriodicalIF":3.1,"publicationDate":"2023-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41239845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Elevated indoleamine 2,3-dioxygenase activity is associated with endothelial dysfunction in people living with HIV and ROS production in human aortic endothelial cells in vitro. 吲哚胺2，3-双加氧酶活性升高与HIV感染者的内皮功能障碍和体外人主动脉内皮细胞中ROS的产生有关。

IF 3.1

Drug Discoveries and Therapeutics Pub Date : 2023-11-18 Epub Date: 2023-10-26 DOI: 10.5582/ddt.2023.01069

Junyang Yang, Rentian Cai, Jingna Xun, Renfang Zhang, Li Liu, Yinzhong Shen, Tangkai Qi, Zhenyan Wang, Wei Song, Yang Tang, Jianjun Sun, Shuibao Xu, Bihe Zhao, Hongzhou Lu, Jun Chen

{"title":"Elevated indoleamine 2,3-dioxygenase activity is associated with endothelial dysfunction in people living with HIV and ROS production in human aortic endothelial cells in vitro.","authors":"Junyang Yang, Rentian Cai, Jingna Xun, Renfang Zhang, Li Liu, Yinzhong Shen, Tangkai Qi, Zhenyan Wang, Wei Song, Yang Tang, Jianjun Sun, Shuibao Xu, Bihe Zhao, Hongzhou Lu, Jun Chen","doi":"10.5582/ddt.2023.01069","DOIUrl":"10.5582/ddt.2023.01069","url":null,"abstract":"The precise role of indoleamine 2,3-dioxygenase (IDO) in cardiovascular diseases (CVD) among people living with HIV (PLWH) is still under debate, despite recognized links. This study aimed to investigate the impact of elevated IDO activity on endothelial dysfunction in PLWH. A total of 38 PLWH, who had not previously received anti-retroviral therapy (ART), were enrolled in the study. These participants were monitored for 36 months following the initiation of ART. Measurements including plasma levels of IDO activity, markers of endothelial dysfunction, inflammatory factors, and lipids. In vitro, human aortic endothelial cells (HAEC) were exposed to interferon-γ, an IDO inhibitor, a kynurenine 3-hydroxylase (KMO) inhibitor, as well as different concentrations of kynurenine. Pre-ART, PLWH demonstrated notably elevated plasma concentrations of soluble intercellular adhesion molecule 1 (sICAM-1), soluble vascular cell adhesion molecule 1(sVCAM-1), and IDO activity in comparison to healthy controls. Post-ART, both IDO activity and sICAM-1 levels experienced a significant decrease, with IDO activity reaching levels comparable to those observed in healthy controls. Furthermore, a positive correlation was observed between IDO activity and sICAM-1 (p = 0.0002), as well as sVCAM-1 (p < 0.0001) before ART. In vitro, the augmentation of kynurenine concentration in the medium and the induction of IDO expression in HAEC resulted in increased production of reactive oxygen species (ROS), with minimal impact on endothelial dysfunction. From these findings, it can be concluded that long-term ART has the potential to restore the heightened IDO activity observed in PLWH. The overexpression of IDO primarily influences the expression of ROS in HAEC.","PeriodicalId":47494,"journal":{"name":"Drug Discoveries and Therapeutics","volume":" ","pages":"312-319"},"PeriodicalIF":3.1,"publicationDate":"2023-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50163248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effectiveness of an artificial intelligence-based training and monitoring system in prevention of nosocomial infections: A pilot study of hospital-based data. 基于人工智能的培训和监测系统在预防医院感染中的有效性:基于医院数据的试点研究。

IF 3.1

Drug Discoveries and Therapeutics Pub Date : 2023-11-18 Epub Date: 2023-09-07 DOI: 10.5582/ddt.2023.01068

Ting Huang, Yue Ma, Shaxi Li, Jianchao Ran, Yifan Xu, Tetsuya Asakawa, Hongzhou Lu

引用次数: 0

A pilot study comparing the disinfecting effects of commercialized stable ClO₂ solution (free of activation) with conventional H₂O₂ on dental unit waterlines in the dental practice setting. 一项比较商业化的稳定ClO2溶液（无活化）和传统H2O2对牙科实践环境中牙科单元水线的消毒效果的初步研究。

IF 3.1

Drug Discoveries and Therapeutics Pub Date : 2023-11-18 Epub Date: 2023-10-26 DOI: 10.5582/ddt.2023.01077

Xiaolei Zhang, Jingjing Sha, Zefan Huang, Sisi Chen, Xufei Luo, Ruijun Liu, Tetsuya Asakawa, Qiang Zhang

{"title":"A pilot study comparing the disinfecting effects of commercialized stable ClO2 solution (free of activation) with conventional H2O2 on dental unit waterlines in the dental practice setting.","authors":"Xiaolei Zhang, Jingjing Sha, Zefan Huang, Sisi Chen, Xufei Luo, Ruijun Liu, Tetsuya Asakawa, Qiang Zhang","doi":"10.5582/ddt.2023.01077","DOIUrl":"10.5582/ddt.2023.01077","url":null,"abstract":"Disinfection of dental unit waterlines (DUWLs) plays a key role in control and prevention of nosocomial infection in a dental clinic. The most conventional disinfectant is hydrogen peroxide (H2O2), while chlorine dioxide (ClO2) has been considered however was limited by the \"activation\" procedures. With the availability of commercialized stable ClO2 solution (free of activation), direct application of ClO2 in the dental practice became possible. This study was designed to compare the disinfecting effects of stable 5 ppm of ClO2 solution with conventional 0.24% of H2O2 on DUWLs in dental practice. Studies of colony-forming units (CFUs), confocal laser scanning microscopy (CLSM) and scanning electron microscope (SEM) were employed for evaluation. In CFUs studies, we found that the efficiency of ClO2 was no less than those of H2O2. In the morphological studies, the stronger disinfecting effects of ClO2 was verified by both CLSM and SEM studies for removal and prevention of biofilm. Importantly, ClO2 solution achieved a better disinfecting efficiency not only at the surface of bacterial biofilm, but also, it has penetrating effects, presented disinfecting effects from the surface to the bottom of the biofilm. This pilot study provided evidence regarding the efficiency of stable ClO2 solution on disinfection of DUWLs in the dental practice setting. Application of stable ClO2 solution in dental practice is therefore become possible.","PeriodicalId":47494,"journal":{"name":"Drug Discoveries and Therapeutics","volume":" ","pages":"357-362"},"PeriodicalIF":3.1,"publicationDate":"2023-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50163247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Development of a simple high-performance liquid chromatography-ultraviolet method for sotorasib quantification in human plasma: Implications for therapeutic drug monitoring. 开发一种简单高效液相色谱-紫外法测定人血浆中索托拉西布的含量：对治疗药物监测的意义。

IF 3.1

Drug Discoveries and Therapeutics Pub Date : 2023-09-15 Epub Date: 2023-08-19 DOI: 10.5582/ddt.2023.01043

Eri Hikita, Yoshito Gando, Hideo Chubachi, Mikio Shirota, Akifumi Kushiyama, Takeo Yasu

{"title":"Development of a simple high-performance liquid chromatography-ultraviolet method for sotorasib quantification in human plasma: Implications for therapeutic drug monitoring.","authors":"Eri Hikita, Yoshito Gando, Hideo Chubachi, Mikio Shirota, Akifumi Kushiyama, Takeo Yasu","doi":"10.5582/ddt.2023.01043","DOIUrl":"10.5582/ddt.2023.01043","url":null,"abstract":"Sotorasib, an oral small-molecule inhibitor, reportedly exerts promising activity against Kirsten rat sarcoma viral oncogene homolog (KRAS)-mutant tumors. However, the currently administered dose may fail to represent the optimal dose based on the therapeutic efficacy. Herein, we developed a simple and sensitive method using high-performance liquid chromatography with ultraviolet (HPLC-UV) to measure the sotorasib concentration in human plasma. The sotorasib calibration curve exhibited linearity across the concentration range of 0.10-20.0 μg/mL (r2 = 0.9999). The coefficients of intra- and inter-day validation ranged between 0.79-9.75% and 3.01-6.13%, respectively. The assay accuracy ranged between -3.14 and 5.18%, with > 98.5% recovery. Subsequently, we applied the developed method to estimate sotorasib concentrations in a patient with KRAS G12C-mutated non-small cell lung cancer. We anticipate that our HPLC-UV method will be valuable for assessing the safety and efficacy of sotorasib in larger patient cohorts.","PeriodicalId":47494,"journal":{"name":"Drug Discoveries and Therapeutics","volume":"17 4","pages":"289-293"},"PeriodicalIF":3.1,"publicationDate":"2023-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10302636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ultrasound-guided brachial plexus block at the clavicle level: A review. 超声引导下锁骨水平臂丛神经阻滞：综述。

IF 3.1

Drug Discoveries and Therapeutics Pub Date : 2023-09-15 Epub Date: 2023-08-17 DOI: 10.5582/ddt.2023.01005

Zhimin Guo, Ming Zhao, Haihua Shu

{"title":"Ultrasound-guided brachial plexus block at the clavicle level: A review.","authors":"Zhimin Guo, Ming Zhao, Haihua Shu","doi":"10.5582/ddt.2023.01005","DOIUrl":"10.5582/ddt.2023.01005","url":null,"abstract":"The supraclavicular block (SCB) and the infraclavicular block (ICB) are introduced to meet upper extremity surgery, where the transducer or the insertion point is placed superiorly and inferiorly at the approximate midpoint of the clavicle, respectively. These two approaches are highly appealing since they clearly exhibited each cord and its associated anatomy. In addition, it directed the needle accurately with real-time imaging by ultrasound guidance. Therefore, it brought higher success rates and fewer complications. Numerous trials have recently been conducted to examine the SCB and ICB regarding the new approach, injection techniques, block dynamics, and complication of hemidiaphragmatic paresis. It was found that both approaches could improve block effectiveness and postoperative analgesia for upper extremity surgery, according to recent studies at the level of the clavicular brachial plexus block. However, there is still a lack of work comparing the clinical performance and effectiveness of both approaches with ultrasonography. This review aims to outline the current available data from clinical trials along with case reports about these two approaches and to describe the findings published in the literature during the previous 5 years. Based on these findings, we attempt to determine whether there exists a one-size-fits-all approach that has the potential to meet upper extremity surgery.","PeriodicalId":47494,"journal":{"name":"Drug Discoveries and Therapeutics","volume":"17 4","pages":"230-237"},"PeriodicalIF":3.1,"publicationDate":"2023-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10295299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Drug resistance and new therapies in gallbladder cancer. 癌症胆囊的耐药性和新疗法。

IF 3.1

Drug Discoveries and Therapeutics Pub Date : 2023-09-15 Epub Date: 2023-08-17 DOI: 10.5582/ddt.2023.01013

Yuxin Sun, Xiaoxuan Li, Haihong Cheng, Shouhua Wang, Di Zhou, Jun Ding, Fei Ma

引用次数: 0